{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:29:45Z","timestamp":1793690985517,"version":"4.5.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111445","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:07:43Z","timestamp":1782338863000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Raafat","family":"Mady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Tafazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-515. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-396. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","article-title":"Mounjaro (tirzepatide) prescribing information","year":"2023","unstructured":"Mounjaro (tirzepatide) prescribing information. Eli Lilly and Company, Indianapolis, US; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-216. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S419304","article-title":"The body weight reducing effects of tirzepatide in people with and without type 2 diabetes: a review on efficacy and adverse effects","volume":"18","author":"Jensen TL","year":"2024","unstructured":"Jensen TL, Br\u00f8nden A, Karstoft K, Sonne DP, Christensen MB. The body weight reducing effects of tirzepatide in people with and without type 2 diabetes: a review on efficacy and adverse effects. Patient Prefer Adherence. 2024, 18:373-382. 10.2147\/PPA.S419304","journal-title":"Patient Prefer Adherence"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090204","article-title":"The effect of tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies","volume":"12","author":"Rochira V","year":"2024","unstructured":"Rochira V, Greco C, Boni S, et al.. The effect of tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies. Diseases. 2024, 12:204. 10.3390\/diseases12090204","journal-title":"Diseases"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2164","article-title":"Tirzepatide and cancer risk in individuals with and without diabetes: a systematic review and meta-analysis","volume":"40","author":"Kamrul-Hasan AB","year":"2025","unstructured":"Kamrul-Hasan AB, Alam MS, Dutta D, Sasikanth T, Aalpona FT, Nagendra L. Tirzepatide and cancer risk in individuals with and without diabetes: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2025, 40:112-124. 10.3803\/EnM.2024.2164","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii GA","year":"2025","unstructured":"Silverii GA, Marinelli C, Bettarini C, Del Vescovo GG, Monami M, Mannucci E. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025, 27:4454-4468. 10.1111\/dom.16489","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40134-025-00433-2","article-title":"Case-based review of breast imaging changes associated with GLP-1 agonists","volume":"13","author":"Villavicencio JJ","year":"2025","unstructured":"Villavicencio JJ, Zuckerman SP. Case-based review of breast imaging changes associated with GLP-1 agonists. Curr Radiol Rep. 2025, 13:2. 10.1007\/s40134-025-00433-2","journal-title":"Curr Radiol Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01208-7","article-title":"Oestrogen changes at menopause: insights into obesity-associated breast risk and outcomes","volume":"22","author":"Sho M","year":"2026","unstructured":"Sho M, Qureshi R, Slingerland J. Oestrogen changes at menopause: insights into obesity-associated breast risk and outcomes. Nat Rev Endocrinol. 2026, 22:166-176. 10.1038\/s41574-025-01208-7","journal-title":"Nat Rev Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli GF","year":"2021","unstructured":"Piccoli GF, Mesquita LA, Stein C, et al.. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021, 106:912-921. 10.1210\/clinem\/dgaa891","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01135-0","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown","volume":"23","author":"Mannucci E","year":"2026","unstructured":"Mannucci E, Dicembrini I. Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown. Nat Rev Clin Oncol. 2026, 23:459-470. 10.1038\/s41571-026-01135-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062790","article-title":"Mammographic density and the risk and detection of breast cancer","volume":"356","author":"Boyd NF","year":"2007","unstructured":"Boyd NF, Guo H, Martin LJ, et al.. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007, 356:227-236. 10.1056\/NEJMoa062790","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01624-5","article-title":"Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study","volume":"25","author":"Masala G","year":"2023","unstructured":"Masala G, Bendinelli B, Caini S, et al.. Lifetime changes in body fatness and breast density in postmenopausal women: the FEDRA study. Breast Cancer Res. 2023, 25:35. 10.1186\/s13058-023-01624-5","journal-title":"Breast Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26839-y","article-title":"Association of body composition fat parameters and breast density in mammography by menopausal status","volume":"12","author":"Chu A","year":"2022","unstructured":"Chu A, Sung P, Lee J, et al.. Association of body composition fat parameters and breast density in mammography by menopausal status. Sci Rep. 2022, 12:22224. 10.1038\/s41598-022-26839-y","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn388","article-title":"Obesity, mammography use and accuracy, and advanced breast cancer risk","volume":"100","author":"Kerlikowske K","year":"2008","unstructured":"Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS. Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst. 2008, 100:1724-1733. 10.1093\/jnci\/djn388","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160809","article-title":"Effects of bariatric surgery on breast density in adult obese women: systematic review and meta-analysis","volume":"14","author":"Sun D","year":"2023","unstructured":"Sun D, Huang Z, Dong W, Zhao X, Liu C, Sheng Y. Effects of bariatric surgery on breast density in adult obese women: systematic review and meta-analysis. Front Immunol. 2023, 14:1160809. 10.3389\/fimmu.2023.1160809","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.03.002","article-title":"Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression","volume":"189","author":"Bhardwaj P","year":"2019","unstructured":"Bhardwaj P, Au CC, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R, Brown KA. Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019, 189:161-170. 10.1016\/j.jsbmb.2019.03.002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00461","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation","volume":"158","author":"Iwaya C","year":"2017","unstructured":"Iwaya C, Nomiyama T, Komatsu S, et al.. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology. 2017, 158:4218-4232. 10.1210\/en.2017-00461","journal-title":"Endocrinology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2436595","article-title":"Tirzepatide for overweight and obesity management","volume":"26","author":"Hamza M","year":"2025","unstructured":"Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025, 26:31-49. 10.1080\/14656566.2024.2436595","journal-title":"Expert Opin Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.46883\/2025.25921046","article-title":"GLP-1 receptor agonist use and weight change in patients with breast cancer","volume":"8","author":"Shen S","year":"2025","unstructured":"Shen S, Bethina Liu Md, Chad Fanti Md, Maria Bromberg Mph, Yuan Chen PhD, Cassandra Chang, Neil M Iyengar Md. GLP-1 receptor agonist use and weight change in patients with breast cancer. Oncology (Williston Park). 2025, 8:294-296. 10.46883\/2025.25921046","journal-title":"Oncology (Williston Park)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0554","article-title":"Weight loss patterns and clinical outcomes of GLP-1 receptor agonists in breast cancer survivors","volume":"6","author":"Sukumar JS","year":"2026","unstructured":"Sukumar JS, Raghavendra AS, Pasyar S, et al.. Weight loss patterns and clinical outcomes of GLP-1 receptor agonists in breast cancer survivors. Cancer Res Commun. 2026, 6:447-455. 10.1158\/2767-9764.CRC-25-0554","journal-title":"Cancer Res Commun"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P2-08-25","article-title":"FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive\/HER2 negative breast cancer","volume":"31","author":"Omene C","year":"2025","unstructured":"Omene C, George M, Kowzun M, et al.. FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive\/HER2 negative breast cancer. Clin Cancer Res. 2025, 31:P2-08-25. 10.1158\/1557-3265.SABCS24-P2-08-25","journal-title":"Clin Cancer Res"},{"key":"ref24","unstructured":"Tirzepatide weight loss for MRD-positive early breast cancer. ClinicalTrials.gov. (2026). Accessed. December 2, 2026: https:\/\/clinicaltrials.gov\/study\/NCT06517212."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00789-w","article-title":"Breast density in MRI: an AI-based quantification and relationship to assessment in mammography","volume":"11","author":"Chen Y","year":"2025","unstructured":"Chen Y, Li L, Gu H, et al.. Breast density in MRI: an AI-based quantification and relationship to assessment in mammography. NPJ Breast Cancer. 2025, 11:115. 10.1038\/s41523-025-00789-w","journal-title":"NPJ Breast Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0792-y","article-title":"Improving breast cancer surgery: a classification and quadrant-by-quadrant atlas for oncoplastic surgery","volume":"17","author":"Clough KB","year":"2010","unstructured":"Clough KB, Kaufman GJ, Nos C, et al.. Improving breast cancer surgery: a classification and quadrant-by-quadrant atlas for oncoplastic surgery. Ann Surg Oncol. 2010, 17:1375-1391. 10.1245\/s10434-009-0792-y","journal-title":"Ann Surg Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/micr.70185","article-title":"Postmastectomy breast reconstruction following massive weight loss: an updated systematic review and identification of research gaps","volume":"46","author":"Paganini A","year":"2026","unstructured":"Paganini A, L\u00f6fstrand J, Mirzaei N, Hansson E. Postmastectomy breast reconstruction following massive weight loss: an updated systematic review and identification of research gaps. Microsurgery. 2026, 46:e70185. 10.1002\/micr.70185","journal-title":"Microsurgery"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134806","article-title":"Optimizing outcomes in oncoplastic breast-conserving surgery","volume":"14","author":"Gozali A","year":"2025","unstructured":"Gozali A, Piper M. Optimizing outcomes in oncoplastic breast-conserving surgery. J Clin Med. 2025, 14:4806. 10.3390\/jcm14134806","journal-title":"J Clin Med"},{"key":"ref29","unstructured":"American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. (2023). Accessed. March 10, 2026: https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-...."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea AD","year":"2025","unstructured":"Oprea AD, Ostapenko LJ, Sweitzer B, et al.. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025, 135:48-78. 10.1016\/j.bja.2025.04.001","journal-title":"Br J Anaesth"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-017-0242-4","article-title":"Mammographic density changes in surgical weight loss-an indication for personalized screening","volume":"18","author":"Partain N","year":"2018","unstructured":"Partain N, Mokdad A, Puzziferri N, et al.. Mammographic density changes in surgical weight loss-an indication for personalized screening. BMC Med Imaging. 2018, 18:10. 10.1186\/s12880-017-0242-4","journal-title":"BMC Med Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/489244-clinical-implications-of-mounjaro-tirzepatide-for-breast-cancer-detection-and-management-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:05:27Z","timestamp":1793689527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/489244-clinical-implications-of-mounjaro-tirzepatide-for-breast-cancer-detection-and-management-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.111445","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}